So here’s the worst-kept secret in oncology: brain cancer sucks – especially glioblastoma (GBM).

It has a median survival of about 15 months and that number has barely moved in twenty years. The standard of care, Temozolomide. Yeah, that was approved in 2005….we’re still using it.

Why are we talking about this now then? Nothing has changed in over 20 years – seems like a dead-end, right?

Well, when I pulled the last 5 weeks of intelligence data from FLYTE, I noticed something…weird.

There were SIXTEEN meaningful moves against brain cancer – in 5 weeks.

Not just little mentions either. I’m talking actual clinical milestones, IND clearances, regulatory designations, and data drops. In five weeks.

That’s not normal.

And when you look closer, these 16 aren’t random.

They cluster into patterns that tell you something about where neuro-oncology is headed.

CLUSTER 1: The AAV invasion

Gene therapy has tried and failed in brain cancer before. But two companies are back with better vectors and smarter payloads.

1. Trogenix just published Nature data showing 83% complete tumor eradication in GBM models after a single injection, no recurrence over 11 months.

The therapeutic? It’s a dual-payload AAV that kills tumor cells and wakes up the immune system – with some IL-12 – simultaneously. Eli Lilly is on the cap table and they’ve got patients dosing.

2. Meanwhile, Siren Biotechnology got IND clearance and Fast Track for SRN-101, another AAV-delivered cytokine therapy for glioma, running at UCSF.

Two AAV gene therapies entering the clinic for brain cancer at the same time is a signal in itself.

CLUSTER 2: The pill makers

Oral drugs for glioblastoma are not unheard of – after all, Temozolomide is taken as a capsule – but they’re rare. The blood-brain barrier is…tough.

So developing an oral drug that ACTUALLY works in the brain has been a NOTORIOUS challenge. That may be changing.

Hemispherian just dosed first patients with GLIX1, a first-in-class TET2 activator that reminds glioma cells they were supposed to differentiate.

FORE Biotherapeutics completed an FDA hat trick for plixorafenib in BRAF-mutated CNS tumors, with registrational data coming by year end.

Myosin Therapeutics opened a Phase 1/2 across all three Mayo Clinic campuses. The brain isn’t impenetrable anymore. People figured out how to drug it orally.

CLUSTER 3: The pediatric push

This is where the story gets heavy.

In one month, three separate companies advanced programs for childhood brain cancers.

Aminex Therapeutics picked up a second Orphan Drug Designation for a polyamine inhibitor in DIPG.

Plus Therapeutics got ODD for a rhenium-186 radiotherapeutic in pediatric gliomas.

Starlight Therapeutics got IND clearance for a brain-penetrant alkylating agent across DIPG, GBM, and medulloblastoma.

And TippingPoint Biosciences closed an oversubscribed $4.5M seed to target DIPG through chromatin remodeling. TippingPoint is backed by a foundation named after a child who died from the disease – Yuvaan Tiwari Foundation…I’m not crying – you’re crying.

Four companies with four different modalities, all trying to save kids. Love to see it.

CLUSTER 4: The wild cards

When your standard approaches don’t work for twenty years, I guess you gotta get creative.

UP Oncolytics presented a Zika virus-derived oncolytic for GBM at AACR. Yes, Zika.

Alpheus Medical started a Phase 2b of sonodynamic therapy, activating a porphyrin compound in tumor tissue with ultrasound.

These are left-field bets from people who looked at the graveyard of failed GBM drugs and decided to try something completely different.

—

And that’s not all…there’s money flying around too.

Servier dropped $2.5 billion to acquire Day One Biopharmaceuticals for Ojemda, a RAF inhibitor already approved in pediatric glioma.

My thoughts here? You don’t pay $2.5 billion for a brain cancer drug unless you think brain cancer drugs are about to start working.

—

So why is this happening now? It’s likely a combination of things:

Better AAV strategies that make “gene therapy for brain cancer” a viable approach.

Epigenetic targets that are finally druggable.

AI drug design that produces compounds with BBB-penetrating capabilities.

Adaptive trial platforms lowering the bar.

And twenty years of failure forcing creativity.

When the obvious targets don’t work, you try Zika. You try ultrasound. You try rewiring how DNA folds.

Obviously, none of these 16 programs are guaranteed to work. GBM has humbled bigger companies with bigger budgets. But for the first time in a long time, the shots on goal actually look different from each other.